Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics

Table 2

Non-anti-TNF-targeted biologics: reported TB cases from national registries and postmarketing surveillance.

Biologic	Country; patient N°	TB cases	IR	Expected IR/100/year (WHO)	Reference
Tocilizumab	Japan; 3881	4	0.22	15–100	[116]
	Japan; 302	0	0	15–100	[115]
Rituximab	France; 1303	0	0	10–24	[142]
	Germany; 370	0	0	10–24	[143]
	Germany; 2484	1	0.12	10–24	[145]
	Greece; 234	0	0	10–24	[144]
	Taiwan; 763	2	0.38	15–100	[140]
Abatacept	France; 682	0	0	10–24	[171]
	Japan; 231	0	0	15–100	[172]
Ustekinumab	Worldwide; 3474	0	0	NA	[180]
Secukinumab	Unavailable data	NA	NA	NA	NA

WHO: World Health Organization-estimated incidence of TB, 2016; NA: not applicable.